Improvement in exercise capacity despite cardiac deterioration: Noninvasive assessment of long-term therapy with amrinone in severe heart failure

Lewis A. Siegel, Thierry H. LeJemtel, Joel Strom, Carol Maskin, Robert Forman, William Frishman, John Wexler, Hillel Ribner, Edmund H. Sonnenblick

Research output: Contribution to journalArticle

12 Scopus citations


Seven patients with severe congestive heart fallure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72). During the first week of therapy, exercise capacity as assessed on a treadmill using the Naughton protocol, increased substantially from 7.6 ± 4.2 to 12.1 ± 4.4 minutes (p < 0.01). At an early period of follow-up (8 to 12 weeks), a further significant increase in exercise capacity to 14.7 ± 5.0 minutes (p < 0.05) was demonstrated, while at a later follow-up exercise capacity had decreased to 11.4 ± 6.8 minutes (p < 0.05). This was still significantly greater than prior to amrinone therapy (p < 0.01). Left ventricular ejection fraction was increased from 14 ± 4 to 19 ± 4% (p < 0.05) during the first week of therapy, but was not significantly different from control at the early and late periods of follow-up. Left ventricular end-diastolic dimension index increased from control value of 43 ± 5 to 47 ± 7 mm/m2 (p < 0.01) at the late period of follow-up. Thus long-term amrinone therapy resulted in a substantial improvement in exercise capacity despite a slow, but progressive decline in cardiac performance.

Original languageEnglish (US)
Pages (from-to)1042-1047
Number of pages6
JournalAmerican heart journal
Issue number5 PART 1
Publication statusPublished - Nov 1983


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this